Optimal Long-term Antiplatelet Regimen for Patients with High Ischaemic and Bleeding Risks After Percutaneous Coronary Intervention

Abstract

Background

To assess an optimal long-term antiplatelet strategy in patients at both high ischaemic and bleeding risks after percutaneous coronary intervention (PCI).

Methods and Results

Patients at high risks of both ischaemia and bleeding were eligible for inclusion. We excluded patients with any ischaemic and major bleeding complications during the mandatory period of dual antiplatelet therapy (DAPT). Clinical outcomes were evaluated in three groups of regimens, namely, clopidogrel monotherapy (CLPD), aspirin monotherapy (ASA), and DAPT group. The primary endpoint was a composite of all-cause death, myocardial infarction, stroke, or major bleeding for 12-month follow-up period. To balance characteristics according to antiplatelet strategies, stabilized inverse probability treatment weighting (IPTW) was conducted. After IPTW adjustment, CLPD group (N = 916) showed significantly lower rate of primary endpoint than DAPT group (N = 949) (hazard ratio [HR] = 2.09, 95% confidence interval [CI] = 1.22–3.60, p = 0.008), but there was no statistical difference between CLPD and ASA groups (N = 838) (HR = 1.46, 95% CI = 0.83–2.54, p = 0.187). Clinical benefits of CLPD over DAPT was mainly driven by the lower incidence of ischemic events (HR = 2.51, 95% CI 1.37–4.61; p = 0.003). Incidence of major bleeding did not differ among groups, but there was an increased bleeding tendency in DAPT group compared to CLPD group (HR = 2.51, 95% CI = 0.85–7.41, p = 0.096).

Conclusion

For patients at high bleeding and ischaemic risk, especially undergoing complex PCI, clopidogrel monotherapy demonstrated a significant net clinical benefit compared to DAPT. Clopidogrel monotherapy showed numerical reductions of bleeding and ischaemic event rates compared to aspirin monotherapy.

Keywords

long-term antiplatelet therapy - high ischaemic risk - high bleeding risk - percutaneous coronary intervention - dual antiplatelet therapy

• References

• 1 Lawton JS, Tamis-Holland JE, Bangalore S. et al; Writing Committee Members. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022; 79 (02) e21-e129
• 2 Byrne RA, Rossello X, Coughlan JJ. et al; ESC Scientific Document Group. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J 2023; 44 (38) 3720-3826
• 3 Mauri L, Kereiakes DJ, Yeh RW. et al; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371 (23) 2155-2166
• 4 Park SJ, Park DW, Kim YH. et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362 (15) 1374-1382
• 5 Hahn JY, Song YB, Oh JH. et al; SMART-DATE investigators. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet 2018; 391 (10127): 1274-1284
• 6 Giustino G, Chieffo A, Palmerini T. et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. J Am Coll Cardiol 2016; 68 (17) 1851-1864
• 7 Hahn JY, Song YB, Oh JH. et al; SMART-CHOICE Investigators. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA 2019; 321 (24) 2428-2437
• 8 Koo BK, Kang J, Park KW. et al; HOST-EXAM investigators. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet 2021; 397 (10293): 2487-2496
• 9 Her AY, Jeong YH, Kim BK. et al; PTRG-DES Consortium Investigators. Platelet function and genotype after DES implantation in East Asian patients: rationale and characteristics of the PTRG-DES consortium. Yonsei Med J 2022; 63 (05) 413-421
• 10 Urban P, Mehran R, Colleran R. et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation 2019; 140 (03) 240-261
• 11 Yeh RW, Secemsky EA, Kereiakes DJ. et al; DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 2016; 315 (16) 1735-1749
• 12 Costa F, Van Klaveren D, Feres F. et al; PRECISE-DAPT Study Investigators. Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting. J Am Coll Cardiol 2019; 73 (07) 741-754
• 13 Lee SH, Jeong YH, Hong D. et al; PTRG-DES Registry Investigators. Clinical impact of CYP2C19 genotype on clopidogrel-based antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc Interv 2023; 16 (07) 829-843
• 14 Mehran R, Rao SV, Bhatt DL. et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123 (23) 2736-2747
• 15 Thygesen K, Alpert JS, Jaffe AS. et al; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol 2018; 72 (18) 2231-2264
• 16 Park Y, Franchi F, Rollini F, Angiolillo DJ. Dual antiplatelet therapy after coronary stenting. Expert Opin Pharmacother 2016; 17 (13) 1775-1787
• 17 Hermiller JB, Krucoff MW, Kereiakes DJ. et al; DAPT Study Investigators. Benefits and risks of extended dual antiplatelet therapy after everolimus-eluting stents. JACC Cardiovasc Interv 2016; 9 (02) 138-147
• 18 Giacoppo D, Matsuda Y, Fovino LN. et al. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J 2021; 42 (04) 308-319
• 19 Gragnano F, Mehran R, Branca M. et al; Single Versus Dual Antiplatelet Therapy (Sidney-2) Collaboration. P2Y₁₂ inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions. J Am Coll Cardiol 2023; 81 (06) 537-552
• 20 Gragnano F, Cao D, Pirondini L. et al; PANTHER Collaboration. P2Y₁₂ inhibitor or aspirin monotherapy for secondary prevention of coronary events. J Am Coll Cardiol 2023; 82 (02) 89-105
• 21 Aggarwal D, Bhatia K, Chunawala ZS. et al. P2Y₁₂ inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials. Eur Heart J Open 2022; 2 (02) oeac019
• 22 Kang J, Park KW, Lee H. et al. Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: the HOST-EXAM extended study. Circulation 2023; 147 (02) 108-117
• 23 Shuldiner AR, O'Connell JR, Bliden KP. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302 (08) 849-857
• 24 Paré G, Mehta SR, Yusuf S. et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010; 363 (18) 1704-1714
• 25 Watanabe H, Domei T, Morimoto T. et al; STOPDAPT-2 Investigators. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA 2019; 321 (24) 2414-2427
• 26 Watanabe H, Morimoto T, Ogita M. et al; STOPDAPT-2 Investigators. Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2. Cardiovasc Interv Ther 2021; 36 (04) 403-415